Guest guest Posted June 10, 2010 Report Share Posted June 10, 2010 Pharnext is repositioning drugs already on the market. It mixes drugs in new ways, combining them in so-called " pleocompounds " (pleodrugs), and administers them in mini-doses to restore normal cell functions while reducing side effects. It is an approach known as " network pharmacology " , which a November 8 article in Nature referred to as " the next paradigm in drug discovery " . It's very exciting to me that human trials will begin before the end of 2010. I remember back in 1990 or 1991 when the mutation for CMT 1A was discovered. Wow, sure have seen alot of progress on CMT in the last 20 years. Gretchen Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.